Develops genetic medicines for retinal diseases, including wet age-related macular degeneration.
Jun 2026Revenue $92.0M/yrExpenses $289M/yr
No trendCash runway ≈ 2.3 years from Jun 2026
Figures by year
When will 4D Molecular Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $92.0M and expenses $289M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $85.2M | $245M | −$160M |
| Dec 2024 | $37.0K | $188M | −$188M |
| Dec 2023 | $20.7M | $134M | −$113M |
| Dec 2022 | $3.13M | $113M | −$110M |
| Dec 2021 | $18.0M | $89.4M | −$71.3M |
| Dec 2020 | $13.6M | $70.3M | −$56.7M |
| Dec 2019 | $6.99M | $57.8M | −$50.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.